#Denmark #Copenhagen #digital health #Pharma #Dawn Health

Dawn Health Secures €11.5 Million Funding

Dawn Health, a prominent player in the global digital health sector, has recently secured a funding round amounting to €11.5 million from its esteemed investors, including Chr. Augustinus Fabrikker and Denmark’s Export and Investment Fund (EIFO). This significant sum is a strategic investment aimed at scaling the company’s innovative platform and expanding its product suite, designed specifically for the needs of global pharmaceutical companies through a Software-as-a-Service (SaaS) model.

Since its inception in 2021, Dawn Health has dedicated itself to developing an exceptional platform tailored for the pharmaceutical industry, focusing on enhancing patient outcomes and treatment management. The Dawn platform and its accompanying product range have already gained traction among leading pharmaceutical giants, including Merck and Novartis. This platform finds applications across various medical fields, including oncology, multiple sclerosis, and niche pediatric diseases such as growth disorders. It enables patients to manage their treatments effectively, report symptoms, and maintain close communication with their healthcare teams.

Dawn Health’s offerings leverage advanced technologies in artificial intelligence, data collection, evidence generation, clinical integration, and personalized healthcare. These capabilities significantly improve both patient care and operational efficiencies within pharmaceutical companies. They position the Dawn platform as a foundational tool for treatment companions, disease management programs, and real-world evidence (RWE) solutions that are defining the next generation of digital health.

"Our aim is to become the leading provider in digital health, driving the next generation of pharmaceutical products and ultimately improving the lives of patients worldwide," stated Alexander Mandix Hansen, CEO of Dawn Health. He emphasized that this funding round will facilitate the company’s ability to broaden its proven platform into new markets, thus amplifying its impact on patient care.

This new phase of growth further cements Dawn Health’s role as a trusted partner for pharmaceutical firms, providing scalable and regulatory-compliant digital health solutions that evolve alongside the complexities of modern medicine. Lars Marcher, Chairman of the company, highlighted the impressive revenue growth and expanded presence in the global pharmaceutical landscape since the major investment in December 2021. With over 100 team members, unique solutions, and robust regulatory infrastructures, Dawn Health is poised for continued rapid growth.

About Dawn Health

Dawn Health is a leader in the digital health space, specializing in the development of Software as a Medical Device (SaMD), Digital Therapeutics (DTx), and connected health solutions. Their product suite accelerates the introduction of digital health solutions, driving innovations to transform the lives of individuals with chronic conditions. By partnering closely with the life sciences sector, Dawn Health aims to deliver empathetic and patient-centered healthcare solutions.

For more information, visit Dawn Health's website.